Anti-apolipoprotein A-1 IgG as an independent cardiovascular prognostic marker affecting basal heart rate in myocardial infarction

European Heart Journal

Volumn 31, Issue 7, 2010, Pages 815-823

  Vuilleumier, Nicolas ^a   Rossier, Michel F ^a   Pagano, Sabrina ^a   Python, Magaly ^a   Charbonney, Emmanuel ^b   Nkoulou, René ^a   James, Richard ^a   Reber, Guido ^a   MacH, Franois ^a   Roux Lombard, Pascale ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Anti apolipoprotein A 1 autoantibody; Autoimmunity; Myocardial infarction; Prognosis; Resting heart rate

Indexed keywords

APOLIPOPROTEIN A1; AUTOANTIBODY; BIOLOGICAL MARKER; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G;

ACUTE CORONARY SYNDROME; ADULT; AGED; ANTIBODY DETECTION; ARTICLE; AUTOIMMUNITY; CARDIOVASCULAR DISEASE; CHRONOTROPISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HEART FAILURE; HEART INFARCTION; HEART RATE; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RESTING HEART RATE; SURVIVAL RATE; ANIMAL; ARRHYTHMIAS, CARDIAC; CEREBROVASCULAR ACCIDENT; DOSE RESPONSE; HEART MUSCLE CELL; IMMUNOLOGY; METABOLISM; MIDDLE AGED; MORTALITY; MYOCARDIAL INFARCTION; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; RAT; REFERENCE VALUE; REPRODUCIBILITY; TREATMENT OUTCOME; VERY ELDERLY; WISTAR RAT;

ACUTE CORONARY SYNDROME; ADULT; AGED; AGED, 80 AND OVER; ANIMALS; APOLIPOPROTEIN A-I; ARRHYTHMIAS, CARDIAC; BIOLOGICAL MARKERS; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART FAILURE; HEART RATE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCYTES, CARDIAC; PROGNOSIS; PROSPECTIVE STUDIES; RATS; RATS, WISTAR; REFERENCE VALUES; REPRODUCIBILITY OF RESULTS; STROKE; TREATMENT OUTCOME;

EID: 77950489726     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehq055     Document Type: Article

References (38)

1. Libby P. Inflammation in atherosclerosis. Nature 2002;420:868-874.
2. Eyre H, Kahn R, Robertson RM, Clark NG, Doyle C, Hong Y, Gansler T, Glynn T, Smith RA, Taubert K, Thun MJ. American Cancer Society; American Diabetes Association; American Heart Association. Preventing cancer cardiovascular disease and diabetes: a common agenda for the American Cancer Society, American Diabetes Association, and the American Heart Association. Circulation 2004; 109:3244-3255.
3. Matsuura E, Kobayashi K, Koike T, Shoenfeld Y. Autoantibody mediated atherosclerosis. Autoimmun Rev 2002;1:348-353.
4. Sherer Y, Shoenfeld Y. Mechanisms of disease: atherosclerosis in autoimmune diseases. Nat Clin Pract Rheumatol 2006;2:99-106.
5. Mustafa A, Ntyanand S, Beglund L, Lithell H, Hol G, Lefvert AK. Circulating immune complex in 50-year old men as strong and independent risk factor for myocardial infarction. Circulation 2000;102:2576-2581.
6. Wu R, Nityanand S, Berglund L, Lithelle Holm G, Lefvert AK. Antibodies against cardiolipin and oxidatively modified LDL in 50 year old men predict myocardial infarction. Arterioscler Thromb Vasc Biol 1997;17:3159-3163.
7. Meroni PL, Peyvandi F, Foco L, Bernardinelli L, Fetiveau R, Mannucci PM, Tincani A. Anti-beta 2 glycoprotein I antibodies and the risk of myocardial infarction in young premenopausal women. J Thromb Haemost 2007;5:2421-2428.
8. Zhu J, Quyyumi AA, Rott D, Csako G, Wu H, Halcox J, Epstein SE. Antibodies to human heat-shock protein 60 are associated with the presence and severity of coronary artery disease: evidence for an autoimmune component of atherogen-esis. Circulation 2001;103:1071-1075.
9. Eriksson S, Hellman J, Pettersson K. Autoantibodies against cardiac troponins. N Eng J Med 2005;352:98-100.
10. Nussinovitch U, Shoenfeld Y. Intravenous immunoglobulin\indications and mechanisms in cardiovascular diseases. Autoimmun Rev 2008;7:445-452.
11. Vuilleumier N, Reber G, Burger D, de Moerloose P, Dayer JM, Roux-Lombard P. Presence of auto-antibodies to apolipoproteine A1 in patients with acute coronary syndrome further links autoimmunity with cardiovascular disease. J Autoimmun 2004;23:353-360.
12. Vuilleumier N, Charbonney E, Fontao L, Alvarez M, Turck N, Sanchez JC, Burkhard PR, Mensi N, Righini M, Reber G, James R, Mach F, Chevrolet JC, Dayer JM, Forstegard J, Roux-Lombard P. Anti-apolipoprotein A-1 IgG are associated with high oxidised low-density lipoprotein levels in acute coronary syndrome. Clin Sci (Lond) 2008;115:25-33.
13. Stoll G, Bendszus M. Inflammation and atherosclerosis. Novel insights into plaque formation and destabilization. Stroke 2006;3:1923-1932.
14. Holvoet P, Mertens A, Verhamme P, Bogaerts K, Beyens G, Verhaeghe R, Collen D, Muls E, Van de Werf F. Circulating oxidized LDL is a useful marker for identifying patients with coronary heart disease. Arterioscler Thromb Vasc Biol 2001;21:844-848.
15. Meisinger C, Baumert J, Khuseyinova N, Loewel H, Koenig W. Plasma oxidized low density lipoprotein, a strong predictor for acute heart disease events on apparently healthy, middle-aged men from the general population. Circulation 2005;112:651-657.
16. Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R, BEAUTIFUL investigators. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet 2008;372:817-821.
17. Kannel WB, Kannel C, Paffenbarger RSJR, Cupples LA. Heart rate and cardiovascular mortality: the Framingham study. Am Heart J 1987;113:1489-1494.
18. Diaz A, Bourassa MG, Guertin MC, Tardif JC. Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J 2005;26:967-974.
19. Kolloch R, Legler UF, Champion A, Cooper-Dehoff RM, Handberg E, Zhou Q, Pepine CJ. Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternational VErapamil-SR/ trandolapril STudy (INVEST). Eur Heart J 2008;29:1327-1334.
20. Rein AJ, Mevorach D, Perles Z, Gavri S, Nadjari M, Nir A, Elchalal U. Early diagnosis and treatment of atrioventricular block in the fetus exposed to maternal anti-SSA/Ro-SSB/La antibodies: a prospective, observational, fetal kinetocardiogram-based study. Circulation 2009;119:1867-1872.
21. Stojanovich L. Autonomic dysfunction in autoimmune rheumatic disease. Autoim-mun Rev 2009;8:569-572.
22. Lalevée N, Rebsamen MC, Barrère-Lemaire S, Perrier E, Nargeot J, Bénitah JP, Rossier MF. Aldosterone increases T-type calcium channel expression and in vitro beating frequency in neonatal rat cardiomyocytes. Cardiovasc Res 2005; 67:216-224.
23. Maturana A, Lenglet S, Python M, Kuroda S, Rossier MF. Role of the T-type calcium channel CaV3.2 in the chronotropic action of corticosteroids in isolated rat ventricular myocytes. Endocrinology 2009;150:3726-3734.
24. Rossier MF, Lenglet S, Vetterli L, Python M, Maturana A. Corticosteroids and redox potential modulate spontaneous contraction in isolated rat ventricular car-diomyocytes. Hypertension 2008;52:721-728.
25. Muto T, Ueda N, Opthof T, Ohkusa T, Nagata K, Suzuki S, Tsuji Y, Horiba M, Lee JK, Honjo H, Kamiya K, Kodama I, Yasui K. Aldosterone modulates I(f) current through gene expression in cultured neonatal rat ventricular myocytes. Am J Physiol Heart Circ Physiol 2007;293:2710-2718.
26. Reber G, Schousboe I, Tincani A, Sanmarco M, Kveder T, de Moerloose P, Boffa MC, Arvieux J. Inter-laboratory variability of anti-beta2-glycoprotein I measurement. A collaborative study in the frame of the European Forum on Antiphospholipid Antibodies Standardization Group. Thromb Haemost 2002;88:66-73.
27. Panza JA, Diodati JG, Callahan TS, Epstein SE, Quyyumi AA. Role of increase in heart rate in determining the occurrence and frequency of myocardial ischemia during daily life in patients with stable coronary artery disease. J Am Coll Cardiol 1992;20:1092-1098.
28. Ingwall JS, Weiss RG. Is the failing heart energy starved? On using chemical energy to support cardiac function. Circ Res 2004;95:135-145.
29. Chatzizisis YS, Coskun AU, Jonas M, Edelman ER, Feldman CL, Stone PH. Role of endothelial shear stress in the natural history of coronary atherosclerosis and vascular remodeling: molecular, cellular, and vascular behavior. J Am Coll Cardiol 2007; 49:2379-2393.
30. Giannoglou GD, Chatzizisis YS, Zamboulis C, Parcharidis GE, Mikhailidis DP, Louridas GE. Elevated heart rate and atherosclerosis: an overview of the patho-genetic mechanisms. Int J Cardiol 2008;126:302-312.
31. Perski A, Hamsten A, Lindvall K, Theorell T. Heart rate correlates with severity of coronary atherosclerosis in young postinfarction patients. Am Heart J 1988;116:1369-1373.
32. Heidland UE, Strauer BE. Left ventricular muscle mass and elevated heart rate are associated with coronary plaque disruption. Circulation 2001;104:1477-1482.
33. Gullestad L, Aass H, Fjeld JG, Wikeby L, Andreassen AK, Ihlen H, Simonsen S, Kjekshus J, Nitter-Hauge S, Ueland T, Lien E, Frøland SS, Aukrust P. Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure. Circulation 2001;103:220-225. (Pubitemid 32095406)
34. Navab M, Anantharamaiah GM, Reddy ST, Fogelman AM. Apolipoprotein A-I mimetic peptides and their role in atherosclerosis prevention. Nat Clin Pract Car-diovasc Med 2006;3:540-547.
35. Persson L, Boren J, Nicoletti A, Hansson GK, Pekna M. Immunoglobulin treatment reduces atherosclerosis in apolipoprotein E2/2 low density lipoprotein receptor 2/2 mice via the complement system. Clin Exp Immunol 2005;142: 441-445.
36. Vassort G, Talavera K, Alvarez JL. Role of T-type Ca2-channels in the heart. Cell Calcium 2006;40:205-220.
37. Hoppe UC, Jansen E, Sudkamp M, Beuckelmann DJ. Hyperpolarization activated inward current in ventricular myocytes from normal and failing human hearts. Circulation 1998;97:55-65.
38. Delgado Alves J, Kumar S, Isenberg DA. Cross-reactivity between anti-cardiolipin, anti-high density lipoprotein and anti-apolipoprotein A-I IgG antibodies in patients with systemic lupus erythematosus and primary antiphopholipid syndrome. Rheumatology 2003;42:893-899.